It is made available under a CC-BY 4.0 International license.

1 **Distinct genomic signatures and modifiable risk factors underly the** 2 **comorbidity between major depressive disorder and cardiovascular disease**

- 3 Jacob Bergstedt \pm ,*,1
- Joëlle A. Pasman±,2 4
- 5 Ziyan Ma $^{\pm,2}$
- 6 Arvid Harder²
- 7 Shuyang Yao^{2, 12}
- 8 Nadine Parker³
- 9 Jorien L. Treur⁴
- 10 Dirk J.A. Smit⁴
- 11 Oleksandr Frei³
- 12 Alexey Shadrin³
- 13 Joeri J. Meijsen⁵
- 14 Oing Shen $1,6,7$
- 15 Sara Hägg²
- 16 Per Tornvall⁸
- 17 Alfonso Buil⁵
- 18 Thomas Werge^{5,9,10,11}
- 19 Jens Hjerling-Leffler¹²
- 20 Thomas D. $Als¹³$
- 21 Anders D. Børglum^{14,15,16}
- 22 Cathryn M. Lewis^{17,18}
- 23 Andrew M. McIntosh^{19,20}
- 24 Unnur A. Valdimarsdóttir^{21,1,22}
- 25 Ole A. Andreassen $3,23$
- 26 Patrick F. Sullivan^{2,24}
- 27 Yi Lu $^{\pm 2}$
- 28 Fang Fang \pm *,1
- 29
- 30 \pm Equal contribution
- 31 *Corresponding authors
- 32
- ¹33 Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- 34 ²Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 35 ³NORMENT Centre, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo
- 36 University Hospital, Oslo, Norway
37 4 Genetic Epidemiology, Department
- ⁴ Genetic Epidemiology, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
⁵ Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Copenhag
- ⁵ Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark
- 39 ⁶Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, Tongji University School
- 40 of Medicine, Shanghai, China
- 41 ⁷ Institute for Advanced Study, Tongji University, Shanghai, China
- 42 ⁸ Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
- ⁹ The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen, Denmark
- ¹⁰ 44 Lundbeck Foundation GeoGenetics Centre, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark
- 45 ¹¹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 46 Denmark
- 47 ¹²Department Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden
- 48 ¹³Department of Molecular Medicine (MOMA), Molecular Diagnostic Laboratory, Aarhus University Hospital, Aarhus,
- 49 Denmark **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**50 ¹⁴ Department of Biomedicine, Aarhus University, Aarhus, Denmark

It is made available under a CC-BY 4.0 International license.

- ¹⁵ The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark
52 ¹⁶Center for Genomics and Personalized Medicine, Aarhus, Denmark
- 52 ¹⁶Center for Genomics and Personalized Medicine, Aarhus, Denmark
53 ¹⁷Social, Genetic and Developmental Psychiatry Centre, King's Colle
- ¹⁷ Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK
- 54 ¹⁸Department of Medical and Molecular Genetics, King's College London, London, UK
- 55 ¹⁹ Centre for Clinical Brain Sciences, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
 56 ²⁰ Centre for Genomics and Experimental Medicine, University of Edinburgh, Edinburgh, UK
- ²⁰ Centre for Genomics and Experimental Medicine, University of Edinburgh, Edinburgh, UK
- ²¹ Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland

⁵⁸ ²² Department of Epidemiology, Harvard TH Chan School of Public Health, Harvard Unive
- ²² Department of Epidemiology, Harvard TH Chan School of Public Health, Harvard University, Boston, Massachusetts, USA
²³ K.G. Jebsen Centre for Neurodevelopmental disorders, University of Oslo and Oslo University Hosp
- ²³ K.G. Jebsen Centre for Neurodevelopmental disorders, University of Oslo and Oslo University Hospital, Oslo, Norway

²⁴ Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, NC, USA
- ²⁴Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, NC, USA

It is made available under a CC-BY 4.0 International license.

Abstract

- Major depressive disorder (MDD) and cardiovascular disease (CVD) are often comorbid, resulting in
- excess morbidity and mortality. Using genomic data, this study elucidates biological mechanisms, key
- risk factors, and causal pathways underlying their comorbidity. We show that CVDs share a large
- proportion of their genetic risk factors with MDD. Multivariate genome-wide association analysis of
- the shared genetic liability between MDD and atherosclerotic CVD (ASCVD) revealed seven novel loci
- and distinct patterns of tissue and brain cell-type enrichments, suggesting a role for the thalamus. Part
- of the genetic overlap was explained by shared inflammatory, metabolic, and psychosocial/lifestyle risk
- factors. Finally, we found support for causal effects of genetic liability to MDD on CVD risk, but not
- from most CVDs to MDD, and demonstrated that the causal effects were partly explained by metabolic
- and psychosocial/lifestyle factors. The distinct signature of MDD-ASCVD comorbidity aligns with the
- idea of an immunometabolic sub-type of MDD more strongly associated with CVD than overall MDD.
- In summary, we identify plausible biological mechanisms underlying MDD-CVD comorbidity, as well
- as key modifiable risk factors for prevention of CVD in individuals with MDD.

It is made available under a CC-BY 4.0 International license.

76 **Main**

77 Major depressive disorder (MDD) and cardiovascular disease (CVD) are highly comorbid^{1,2}. Several 78 mechanisms might explain the observed comorbidity². One explanation is that genetic risk factors for 79 MDD and CVDs overlap^{3,4}. While observed genome-wide genetic correlations between MDD and CVD 80 are modest²⁻⁴, this may be because local genetic correlations of opposing directions attenuate 81 correlations on the genome-wide level, leading to an underestimation of the genetic overlap⁵. The large 82 polygenicity of MDD⁶ might also mask subtypes with stronger genetic relationships to CVD.

83

84 The observed MDD-CVD comorbidity could also be due to non-genetic factors⁷. Cardiovascular risk 85 factors like high systolic blood pressure, high body mass index (BMI), high levels of low-density 86 lipoprotein cholesterol, high levels of physical inactivity, presence of type 2 diabetes, and smoking have 87 all been associated with $MDD⁸⁻¹⁰$. Moreover, accumulating data show that psychosocial/lifestyle 88 factors associated with MDD, like low educational attainment, exposure to childhood maltreatment, 89 . loneliness, and atypical sleep patterns, are also important risk factors for CVD^{11-14} .

90

91 One common mechanism underlying MDD, CVD, as well as their shared risk factors could be chronic 92 inflammation. Atherosclerosis, the accumulation of fibrofatty lesions in the arterial wall, is the main 93 . cause of $CVD¹⁵$. The build-up of atherosclerotic plaque is a long-term inflammatory process mediated 94 by immune components in crosstalk with arterial wall cells¹⁶. Many lines of evidence also support a 95 role for inflammation in $MDD¹⁷$. Excessive or long-term psychosocial stress promote the maturation 96 and release of inflammatory cytokines like interleukin (IL)-6, which activate the central nervous system 97 to produce behaviors related to $MDD¹⁸$. Importantly, low-grade inflammation, defined by high C-98 reactive protein levels, has been observed in more than a quarter of patients with depression¹⁹, 99 suggesting the presence of an inflammatory subtype of $MDD²⁰$, which might be especially strongly 100 associated with CVD.

101

 The full extent of the genetic overlap between MDD and CVD has not been explored. It remains unknown if the genetic overlap is associated with specific tissues or brain cell-types, or how this overlap relates to shared risk factors such as blood pressure, psychosocial/lifestyle traits, metabolic traits, and 105 inflammation. Moreover, causal effects linking these traits are not fully understood $21-24$.

106

 Here, we dissect the genetic overlap between MDD and CVD (coronary artery disease, peripheral artery disease, heart failure, stroke, and atrial fibrillation) by leveraging state-of-the-art genomic data and methods (Fig. 1). We used newly released summary statistics from a genome-wide association study 110 (GWAS) of MDD involving 290,000 cases⁶, with substantially increased statistical power compared to previous GWASs. First, we assessed the pairwise genetic overlap between MDD and CVD on the genome-wide level, as well as on the level of local partitions of the genome and overlapping causal 113 variants with MiXeR²⁵ and LAVA²⁶. Using these methods, we were able to consider the direction of correlation at each locus in the genome, providing a more granular understanding of the genetic overlap between MDD and CVD. Second, we identified genetic variants and genes that contribute to the shared liability between MDD and atherosclerotic CVD (ASCVD; coronary artery disease, peripheral artery 117 disease, heart failure, and stroke) using Genomic Structural Equation Modeling (SEM)²⁷. We mapped identified variants to brain cell-types using novel annotations based on single-cell RNA sequencing in 119 post-mortem human brain samples²⁸. Third, we assessed shared risk factors explaining the association between MDD and CVD. To do so, we evaluated the polygenic overlap between MDD and well- established risk factors. We then estimated genetic correlation between MDD and CVD adjusting for risk factors, and the genetic correlation between the shared genetic liability between MDD and ASCVD

It is made available under a CC-BY 4.0 International license.

- 123 and risk factors. Finally, we used Mendelian Randomization (MR) to investigate putative causal effects
- 124 and assess mediation through shared risk factors for MDD and CVD. In brief, this study leverages recent
- 125 large-scale GWAS data and triangulates results from current genomic methods to elucidate etiological
- 126 pathways underlying the comorbidity between MDD and CVD.

*: Atherosclerotic Cardiovascular Disease (ASCVD) does not encompass atrial fibrillation.

- 128 **Figure 1.** Graphical abstract illustrating the study approach. The comorbidity between MDD and CVD 129 is investigated using genetic and causal inference methods, including assessing overlap with and
- 130 mediation through shared risk factors (metabolic, psychosocial/lifestyle, inflammatory, and blood

It is made available under a CC-BY 4.0 International license.

- 131 pressure; Supplementary Table 1). The risk factor group psychosocial/lifestyle is abbreviated to
- 132 psychosocial. Created with BioRender.com (license agreements VG26BG3VTL, MK26BG46H3).

It is made available under a CC-BY 4.0 International license.

Results

Most genetic risk factors for CVD overlap with MDD

 There were weak to moderate genome-wide genetic correlations between MDD and CVDs, as estimated 136 with linkage disequilibrium score regression (LDSC²⁹; Extended Data Fig. 1, Supplementary Table 2). Information on source GWASs for all traits is given in Supplementary Table 1. The strongest 138 correlations were noted for peripheral artery disease $(r_g=0.30, SE=0.04, P=1\times10^{-13})$, heart failure $(r_g=0.29, \text{ SE}=0.03, P=1\times10^{-24})$, and coronary artery disease $(r_g=0.25, \text{ SE}=0.02, P=9\times10^{-45})$, while 140 smaller but statistically significant correlations were observed for stroke and atrial fibrillation $(r_e=0.18)$ 141 and r_e =0.11, P <1×10⁻⁷). ASCVDs showed strong correlations among each other, while atrial fibrillation was only moderately genetically correlated to the ASCVDs (Extended Data Fig. 2a, Supplementary Table 2). To aid interpretation of these results, we also analyzed specific MDD symptoms. Poor appetite or overeating was consistently the symptom that showed the strongest genetic correlation to the CVDs (Extended Data Fig. 1a).

We then estimated local genetic correlations between MDD and CVDsin each of 2,495 distinct genomic

148 regions used in LAVA²⁶. The distribution of local genetic correlations is displayed in Fig. 2a, with points exceeding the horizontal line representing partitions with a genome-wide significant correlation

 (*PFDR*<0.05). We found 54 significant local correlations between MDD and CVDs, 40 of which were for MDD and coronary artery disease. Mostsignificant local correlations were positive (90%), although

results were mixed for peripheral artery disease and heart failure, with 50% and 25% of the partitions,

 respectively, showing negative correlations with MDD (Supplementary Table 4). We also investigated local genetic correlation between MDD and the CVDs in 16 loci in the human leukocyte antigen (HLA)

region (Extended Data Fig 1b). Out of 50 assessed local genetic correlations, 8 were significant,

indicating that this region is a hotspot of genetic correlation between MDD and CVDs.

158 Next, we investigated genetic overlap on the level of risk variants using $MiXeR^{25}$ (Supplementary Tables 5-6). We identified more variants for MDD than for the CVDs, suggesting that MDD is more polygenic than CVD. To verify these results, we estimated polygenicity using a complementary 161 Bayesian approach implemented in $SBaves³⁰$, which showed estimates that were highly correlated with those of MiXeR (Extended Data Fig. 2b , Supplementary Table 7).

 Bivariate MiXeR results showed that CVDs shared a large proportion of their causal variants with MDD (from 64% in atrial fibrillation to 92% in heart failure, Fig. 2b) whereas MDD shared only a small proportion of its causal variants with CVDs (<20%). Note that for peripheral artery disease the performance metrics of the model indicate that this finding needs to be interpreted with caution (Supplementary Table 6). Both shared genetic variants and local genetic correlations exhibit strong degrees of effect direction concordance (Fig. 2c), suggesting that genetic risk variants for CVDs are

strongly correlated with a genetic subcomponent of MDD.

It is made available under a CC-BY 4.0 International license.

172 **Figure 2.** Genetic overlap between MDD and CVD beyond genome-wide genetic correlation. (**a)** 173 Volcano plots based on LAVA results showing genomic loci (green dots) with the local genetic 174 correlation between MDD and each of the CVDs (x-axis) and the corresponding *P*-value (y-axis). Loci 175 exceeding the horizontal line are significant at *P_{FDR}*<0.05. Multiple testing was performed separately 176 for each trait over all considered loci (**b)** Venn diagrams based on MiXeR results showing the number 177 of causal variants that are unique to MDD (left circle), unique to CVD (non-overlapping part of right 178 circle), or shared between MDD and CVD (overlapping part of circles). (**c)** Genetic correlation 179 estimated by LDSC (x-axis) against the percentage of MDD variants that are shared with the CVD trait 180 as estimated by MiXeR (first plot), the percentage of CVD variants that are shared with MDD (second 181 plot), and the percentage of CVD variants that are shared with MDD that have concordant effect 182 directions (third plot). The fourth plot shows the percentage of local genetic correlations from LAVA 183 that have concordant effect directions on the y-axis. **a-c** Sample sizes and information for underlying 184 summary statistics GWASs are reported in Supplementary Table 1.

185 MDD=Major Depressive Disorder, PAD=Peripheral Artery Disease, CAD=Coronary Artery Disease, AF=Atrial Fibrillation,

186 HF=Heart Failure

It is made available under a CC-BY 4.0 International license.

Shared genetic liability to MDD and CVD

 To further characterize the genetic overlap, we explicitly modelled the shared liability between MDD and CVD as a higher-order latent factor using Genomic SEM. We excluded atrial fibrillation because it 190 deteriorated the model fit (CFI=0.918, SRMR=0.072) and had the lowest factor loading (β =0.56, SE=0.05), so that the interpretation of the latent factor changed to representing ASCVD. The final model had an excellent fit with Comparative Fit Index CFI>0.999 and Standardized Root Mean Squared 193 Residual SRMR=0.021. The factor loading for MDD was β =0.32. The loadings for the ASCVDs ranged from β =0.63 for stroke (SE=0.06, *P*=4.37×10⁻⁴¹) to β =0.85 for heart failure (SE=0.07, *P*=2.97×10⁻⁵⁶) (loadings standardized on the latent factors are shown in Fig. 3a). For comparison, we also fit a latent factor for the ASCVDs alone (without MDD), which showed similar fit and parameter estimates (CFI>0.999, SRMR=0.013) (Extended Data Fig. 3a). This shows that shared genetic liability to different ASCVDs as well as to ASCVDs and MDD (to a lesser extent) can be explained by a single underlying factor.

 The GWAS on the latent MDD-ASCVD factor resulted in 205 independent genome-wide significant 202 loci (Fig. 3b, independent at $R^2 < 0.1$ and distance \geq 250kb, Supplementary Table 8). We did not observe genomic inflation, indicating that results were not strongly affected by population stratification (LDSC intercept=1.02). Almost three quarters (74.6%) of the genome-wide statistically significant SNPs showed a high Q heterogeneity, suggesting that their effects were more in line with an independent pathway than a common pathway model (see methods). Most of this heterogeneity was due to MDD, as the GWAS for latent ASCVD without MDD showed fewer genome-wide statistically significant SNPs with a high heterogeneity (30.6%; Extended Data Fig*.* 3b).

 For the latent MDD-ASCVD factor, we filtered out variants that showed significant heterogeneity and considered only variants where the latent MDD-ASCVD factor was the best model for the follow-up analyses. We retained 72 independent loci underlying the shared genetic liability (Fig. 3b, Supplementary Table 9). The top SNP after filtering was rs11670056 in the *ELL* gene on chromosome 19, which is part of the transcription elongation factor complex and has previously been associated with a range of CVDs, blood traits, BMI, and educational attainment (enrichment in associations with other traits for significant SNPs are shown in Extended Data Fig. 4a). There were 19 top SNPs that were significant eQTLs for one or multiple genes (top 10 are annotated in Fig. 3b, full results are shown in Supplementary Table 10). Besides *ELL,* multiple genes on chromosome 10 around *INA* and *CNNM2* were identified. *INA* is involved in structural neuron regulation whereas *CNNM2* is involved in ion transportation and has previously been associated with psychiatric as well as cardiovascular traits.

 From the latent MDD-ASCVD GWAS summary statistics we extracted seven novel loci that were not among the risk loci in the MDD and ASCVD GWASs that constituted the latent factor (Extended Data Fig. 4b, Supplementary Table 11). The top SNPs in these loci have not been identified in any GWAS recorded in the GWAS catalog before, but four of them have shown suggestive associations (*P*<0.05)

- with metabolic traits (rs11065577, rs11606884, rs2838351, and rs500571).
-

 Using partitioned LDSC, we observed that the heritability of the latent MDD-ASCVD factor was enriched in genes with expression specific to endothelial and blood vessel tissues, which was also observed for latent ASCVD, but not for MDD (Fig. 3c, Supplementary Table 12). To gain deeper insights into brain-specific mechanisms, we leveraged high-resolution human brain single-nucleus 232 RNAseq data²⁸ and identified four human brain cell-types that exhibited enriched MDD-ASCVD heritability, including deep layer corticothalamic and 6b cells, midbrain-derived inhibitory neurons,

It is made available under a CC-BY 4.0 International license.

 miscellaneous neurons, and vascular cells (Fig. 3d, Supplementary Table 13). Notably, three of the four cell-types were uniquely associated with the latent MDD-ASCVD factor, displaying no enrichment for either latent ASCVD without MDD or MDD only, suggesting that the genetic variance for MDD-ASCVD comorbidity has a distinct functional signature.

 To externally validate the MDD-ASCVD phenotype, we computed polygenic risk scores (PRS) based on the summary statistics for the latent MDD-ASCVD factor, as well as for MDD and latent ASCVD, and found them to significantly predict ASCVD and MDD diagnoses in UK Biobank (UKB) (all $P < 2 \times 10^{-13}$; Supplementary Tables 14-15; note that source and target samples were overlapping and the 243 R² values should only be interpreted relative to one another). The PRS for latent ASCVD and the latent MDD-ASCVD factor explained similar amounts of variance in ASCVD (Fig. 3e). This is in line with the MiXeR findings (Fig. 2b), suggesting that most causal variants for ASCVD are shared with MDD. In contrast, as most causal variants for MDD are not shared with ASCVD, the PRS for the latent MDD-ASCVD factor explained less than half as much variance in MDD as the MDD PRS.

 Next, we assessed genetic correlations between the latent MDD-ASCVD factor and MDD symptoms. We found that poor appetite or overeating and suicidal thoughts are the symptoms most strongly

correlated with MDD-ASCVD. In contrast, poor appetite or overeating is among the least genetically

correlated symptoms to MDD (Extended Data Fig. 4c).

 Finally, we estimated genetic correlation of attention deficit and hyperactivity disorder (ADHD), anxiety disorders, post-traumatic stress disorder, bipolar disorder, and schizophrenia, with MDD,

MDD-ASCVD, and ASCVD. We found that ADHD, anxiety disorder, and PTSD were genetically

 correlated with ASCVD (Extended Data Fig. 4d). In addition, PTSD and ADHD showed similar genetic correlations for MDD and MDD-ASCVD, which might suggest that the variants that are common to

MDD and ASCVD explain most of the genetic correlation between MDD and these disorders.

260

 Figure 3. Shared genetic liability factor for MDD-ASCVD. (**a)** Latent factor model as specified in Genomic SEM with the 'observed' variables in rectangles and the latent variables in circles. Factor loadings (standardized on the latent factors) are given in black and variances in blue. Sample sizes for underlying GWAS summary statistics are reported in Supplementary Table 1 (**b)** Latent MDD-ASCVD factor GWAS results. The x-axis shows genomic position, and the y-axis shows statistical significance 266 as $-\log_{10}(P)$. Genome-wide significant SNPs that were filtered out because of significant heterogeneity 267 Q_{SNP} are displayed in grey. The top 10 eQTL genes are displayed with dashed vertical lines indicating their position. (**c)** Enrichment results in GTEx tissues for the latent MDD-ASCVD factor, with latent ASCVD (without MDD) and MDD-only as comparison. (**d)** Enrichment results for the latent MDD- ASCVD factor, latent ASCVD, and MDD-only in brain cell types. **(e)** Proportion of variance explained in MDD and CVD phenotypes in the UKB (defined using ICD-codes listed in Supplementary Table 14) by each of 3 PRSs for the latent MDD-ASCVD factor, latent ASCVD, or MDD-only. **c, d** Enrichment is measured using significance testing in a two-sided t-test displayed as -log10(*P*). Only tissues with a 274 significant association (P_{FDR} <0.05) are shown. Multiple testing was performed over tested tissues/cell-275 types.

It is made available under a CC-BY 4.0 International license.

276 MDD=Major Depressive Disorder; MDD-ASCVD=common factor for MDD and ASCVD; ASCVD=common factor for the

atherosclerotic cardiovascular diseases

Polygenic overlap between MDD and risk factors

 Next, we aimed to identify risk factors that contribute to the genetic and phenotypic association between MDD and CVD. First, we assessed the genome-wide genetic correlations between MDD and risk factors. Confirming previous findings, we observed strong to moderate genetic correlations of MDD with psychosocial/lifestyle factors, such as loneliness (*rg*=0.68, SE=0.02), childhood maltreatment $(r_g=0.55, SE=0.02)$, and exercise $(r_g=0.33, SE=0.02)$ (Fig. 5, Extended Data Fig. 6). Among metabolic 284 factors, MDD showed the strongest genetic correlation with type II diabetes $(r_g=0.19, \text{ SE}=0.018)$, followed by levels of high-density lipoprotein cholesterol (*rg*=-0.14, SE=0.01) and triglycerides $(r_g=0.18, SE=0.02)$. MDD showed weak but statistically significant genetic correlations with other metabolic factors (i.e., BMI, non-high-density lipoprotein, low-density lipoprotein, and total 288 cholesterol) $(r_e < 0.15)$. We observed significant genetic correlations for MDD with the inflammatory 289 markers IL-6 (r_g =0.22, SE=0.06) and C-reactive protein (r_g =0.15, SE=0.02). We did not observe genetic correlation of MDD with blood pressure traits. As a comparison, for CVDs, the largest genetic 291 correlations were found between heart failure and BMI ($r_g=0.55$, SE=0.03) and type II diabetes ($r_g=0.49$, SE=0.03) (Extended Data Fig. 5, Supplementary Table 2). Results for MDD symptoms largely followed the pattern of MDD diagnosis, although changed appetite showed stronger genetic correlations with metabolic factors than did MDD diagnosis (Extended Data Fig. 6, Supplementary Table 3).

 Causal variant and local genetic correlation analysis revealed several distinct patterns of polygenic overlap between MDD and risk factors. We found that psychosocial/lifestyle factors, childhood maltreatment, and BMI showed similar levels of polygenicity to MDD (Extended Data Fig. 2b, Supplementary Tables 5 and 7). In addition, they exhibited a large degree of shared variants and many local genetic correlations with MDD (Fig. 4a*,* Extended Data Fig. 7*,* Supplementary Tables 4 and 6). Out of these factors, loneliness and childhood maltreatment also showed high levels of effect direction concordance (93% and 73% of shared causal variants and 85% and 75% of significant local genetic correlations for loneliness and childhood maltreatment were in the same direction; Fig. 4b*,* correlation coefficients are shown in Supplementary Tables 4 and 6). Combined with high polygenicity, such concordance translates to large genome-wide genetic correlations. In contrast, educational attainment, smoking, exercise, physical activity, BMI, and sleep duration had similar levels of polygenicity and a large degree of polygenic overlap with MDD, but low effect direction concordance, suggesting that genome-wide genetic correlations underestimate the polygenic overlap with MDD for these traits.

 Genetic factors for blood pressure traits showed unique patterns of polygenic overlap in that they were polygenic (>5,000 causal variants; Extended Data Fig. 2b) but did not overlap strongly with genetic risk factors for MDD (<0.30 of risk variants overlapping; *Fig.* 4a). Moreover, risk variants that did overlap showed low degree of effect direction concordance (48%-57% of shared variants in the same direction; Fig. 4b). We observed 97 significant local genetic correlations for the three blood pressure traits, 60% of which were positive. These findings suggest that MDD and blood pressure share variants that exhibit both positive and negative correlations, which are cancelled out in the genome-wide estimate.

 Type II diabetes, lipid traits, and C-reactive protein showed low polygenicity (<2,500 causal risk variants). Total cholesterol, non-high-density lipoprotein, and low-density lipoprotein did not share the majority of their risk variants with MDD, and shared variants showed low degrees of effect direction concordance. However, like the CVDs, type II diabetes, triglyceride levels, and C-reactive protein levels

shared most of their risk variants with MDD, and these variants showed high degrees of concordance

It is made available under a CC-BY 4.0 International license.

324 with MDD, in consistently opposite directions.

326 **Figure 4.** Local and causal-variant level genetic correlations between MDD and risk factors. The legend 327 is shared among all panels. (**a)** Venn diagrams based on MiXeR results showing the number of causal 328 variants that are unique to MDD (left circle), the risk factor (non-overlapping part of right circle) or 329 shared between MDD and the risk factor (overlapping part of circles). (**b)** Genome-wide genetic 330 correlation estimated by LDSC (rg, x-axis) against the percentage of MDD causal variants that are 331 shared with the risk factor as estimated by MiXeR (top left), the percentage of risk factor causal variants 332 that are shared with MDD (top right), the percentage of risk factor causal variants that are shared with 333 MDD that have concordant effect directions (bottom left). The bottom right plot shows the percentage

It is made available under a CC-BY 4.0 International license.

- of local genetic correlations from LAVA that have concordant effect directions on the y-axis.
- Cardiovascular traits are also shown for comparison. **a, b** Standard errorsfor MiXeR, LAVA, and LDSC
- results are reported in Supplementary Tables 2-6. Sample sizes for GWAS summary statistics are
- reported in Supplementary Table 1. Note that IL6 was excluded from MiXeR results because it failed
- performance checks (see methods).
- Psychosocial=Psychosocial/Lifestyle; PAD=Peripheral Artery Disease, CAD=Coronary Artery Disease, AF=Atrial
- Fibrillation, HF=Heart Failure, DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes;
- TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol;
- LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein;

Risk factors explain part of the genetic correlation between MDD and CVD

- To assess the degree to which risk factors explain the genetic overlap between MDD and CVD, we estimated genetic correlations adjusted for risk factors (individually or as a group) using Genomic SEM (Fig. 5a; results per individual risk factor are shown in Extended Data Fig. 8 and Supplementary Table Table 16). The largest reduction in point estimate was observed for the genetic correlation between MDD and peripheral artery disease after adjustment for the group of psychosocial/lifestyle factors, indicating that these risk factors explain much of the genetic correlation between MDD and peripheral artery disease. Similarly, the genetic correlation between MDD and coronary artery disease, as well as the latent CVD factor, were attenuated after adjusting for psychosocial/lifestyle factors. The reduction was mainly driven by loneliness (Extended Data Fig. 8). Genetic correlations of MDD with peripheral artery disease and stroke were no longer significant after adjusting for psychosocial/lifestyle factors. We also observed some attenuation in the genetic correlation between MDD and CVD after adjusting for childhood maltreatment, metabolic factors, or inflammatory markers, although confidence intervals overlapped.
-

 Next, we specified the risk factors as mediators instead of covariates in the Genomic SEM model and compared the path estimates from MDD to CVD. Observing attenuation in the association between MDD and CVD when a risk factor is modelled as a mediator rather than a covariate supports the interpretation that the risk factor mediates some of the link between MDD and CVD. For all psychosocial/lifestyle factors together, the inflammation traits, and for type II diabetes, the 95% confidence intervals did not overlap between the mediator and covariate models, suggesting that these risk factors are mediating part of the link between MDD and CVD (Supplementary Table 17).

 Finally, we estimated genetic correlations between the risk factors and the latent MDD-ASCVD factor (Fig. 5b) and found that the latent MDD-ASCVD factor was substantially more genetically correlated with blood pressure traits, C-reactive protein levels, and metabolic factors than MDD only, suggesting that these factors characterize the genetic liability to MDD-ASCVD rather than to MDD alone.

-
-

- 373
- 374

 Figure 5. Genome-wide correlations between MDD and risk factors. (**a)** Genetic correlation between MDD and CVD before and after adjustment for groups of risk factors (color coded). (**b)** Comparison of genetic correlation between MDD (dark green) and the latent CVD-ASMDD factor (lilac) and individual risk factors. **a, b** Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1.

 Psychosocial=Psychosocial/Lifestyle; MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

385 **Causal pathways linking MDD and CVD**

 We investigated putatively causal relationships between MDD and CVD using two-sample MR. Results from the inverse variance-weighted (IVW) estimator are presented in Fig. 6a-c (full results including sensitivity analyses Supplementary Table 18). Instruments were Steiger filtered, i.e., SNPs explaining significantly more variance in the outcome than the exposure were excluded. The results provide support for a causal effect of MDD liability on all CVDs, with the strongest effects observed for coronary and peripheral artery disease. There was no statistically significant pleiotropy for the CVD outcomes, and the results were consistent across weighted median, mode, and Egger sensitivity analyses, providing support for the IVW estimates. Concerning risk factors, we observed no support for a causal effect of MDD liability on levels of blood pressure, physical activity, sleep duration, or IL6. However, increased liability to MDD was associated with increased risk of loneliness, smoking, type II diabetes, and levels of C-reactive protein (Fig. 6a). The results were again consistent across sensitivity analyses. There was statistically significant pleiotropy between MDD and triglycerides, rendering this effect uninterpretable. The average instrument strength of MDD was F=33. Heterogeneity across instruments was statistically significant for most outcomes, suggesting variable effects (Supplementary Table 18).

It is made available under a CC-BY 4.0 International license.

 We also investigated the potential causal effect in the other direction with genetic instruments to CVDs and risk factors as exposures and MDD as outcome (Fig*.* 6b). We provide evidence for a statistically significant causal effect of stroke, loneliness, smoking, exercise, educational attainment, childhood maltreatment, high-density lipoprotein, and BMI on MDD risk (Fig. 6b), which was robust across the sensitivity analyses. No robust effects were observed for other CVDs, blood pressure, other metabolic traits, or inflammatory markers.

 When using genetic instruments for the latent MDD-ASCVD factor to predict the risk factors, statistically significant effects were observed for pulse pressure and type II diabetes (Extended Data Fig. 9c). There was statistically significant pleiotropy only for systolic blood pressure. There were small effects on BMI, childhood maltreatment, educational attainment, high-density lipoprotein, exercise, loneliness, and smoking, but these were less robust across sensitivity analyses (Supplementary Table 18). For most outcomes, there was statistically significant instrument heterogeneity.

 We extended univariable results with multivariable MR to assess if there was support for causal effects of MDD on CVD explained by the risk factors. We included only risk factors that were statistically significantly predicted by MDD in the univariable MR analysis. Fig. 6c shows that, as in the Genomic SEM analyses, the effect of MDD on CVD was attenuated after adjusting for groups of risk factors, although confidence intervals were wide. Results for individual risk factors are shown in Extended Data Fig. 10 and Supplementary Table 19. The effect of MDD liability on peripheral artery disease, heart failure, stroke, and atrial fibrillation risk was no longer statistically significant after adjusting for the groups of metabolic or psychosocial/lifestyle factors, although the confidence intervals overlapped with those from the unadjusted estimates. Likewise, the effect of MDD on atrial fibrillation was no longer statistically significant after adjusting for childhood maltreatment. In Fig. 6d we show a schematic overview of results from all MR analyses.

 To investigate possible bias due to sample overlap, we repeated the main IVW analyses using MDD summary statistics based on GWAS excluding the UKB sample (the main source of overlap). We observed small differences in the estimates, but the interpretation remained the same for all results (Extended Data Fig. 9a-b, Supplementary Table 20). Furthermore, we repeated the analyses using 432 Latent Heritable Confounder (LHC) MR, which is robust to sample overlap³¹. The results pattern was similar, although the point estimates were slightly attenuated for CVD risk (e.g., no longer statistically significant for heart failure and atrial fibrillation) and became stronger for most other traits (Extended Data Fig. 9c). We conclude that although sample overlap impacted the point estimates, the interpretation of results remained similar.

It is made available under a CC-BY 4.0 International license.

438

439 **Figure 6.** Results from univariable and multivariable MR (IVW estimates). (**a)** Effect of liability to 440 MDD (exposure) on CVD and risk factors (outcomes). (**b)** Effects in the opposite direction with MDD 441 as outcome and CVD and risk factors as exposures. (**c)** Effects of MDD on CVD while adjusting for 442 groups of risk factors in multivariable MR. (**d)** Schematic overview of levels of evidence for causal 443 effects, with solid lines indicating convincing evidence (consistent across sensitivity analyses) for such 444 effects, and dashed lines indicating evidence for some of the relationships tested within the trait 445 categories. The arrows from the risk factors to the association between MDD and the CVDs indicate 446 that the combined risk factors attenuated the association so that it was no longer statistically significant. 447 **a-d** Points and error bars represent regression coefficients and 95% CIs. Sample sizes for GWAS 448 summary statistics are reported in Supplementary Table 1. The term beta refers to the log odds ratio.

449 * Indicates that the observed statistically significant association suffered from pleiotropy; possible 450 causal effect should not be interpreted.

451 Psychosocial=Psychosocial/Lifestyle; MDD=Major Depressive Disorder; MDD-ASCVD=common factor for CVD and MDD 452 and ASCVD; PAD=Peripheral Artery Disease; HF=Heart Failure; STR=Stroke; CAD=Coronary Artery Disease; AF=Atrial

It is made available under a CC-BY 4.0 International license.

Fibrillation; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment;

Phys. Act.=Physical activity; Child. Mal.= Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-

Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein;

IL6=Interleukin-6; CRP=C-Reactive Protein; MR=Mendelian randomization IVW=Inverse Variance Weighted.

Discussion

 Here, we showed that genetic risk factors for CVD overlap strongly with MDD. We modeled the shared genetic liability between MDD and ASCVD as a latent factor and showed that, distinct from MDD alone, it is associated with gene expression specific to thalamic and vascular cell-types in the brain and is genetically correlated with immunometabolic factors and blood pressure. Further, we showed that the association between MDD and CVD is partly explained by modifiable risk factors and provide evidence

- that it is likely causal in nature.
-

 In line with previous results $32-35$ we found weak to moderate genome-wide genetic correlations between MDD and CVDs. Analysis on the level of shared risk variants showed that MDD was substantially more polygenic than the CVD traits and that most risk variants for CVD were in fact shared with MDD and had concordant effect directions. In addition, we found many positive local genetic correlations between MDD and CVD, especially for coronary artery disease although that might reflect the fact that the coronary artery disease GWAS have substantially larger effect sample size than the GWASs of the other CVDs. Interestingly, we found that the *HLA* region was a hotspot for local genetic correlation between MDD and CVDs. These findings suggest that genetic overlap between MDD and CVD is underestimated in genome-wide correlation analyses.

 We modelled the shared liability between MDD and ASCVD as a latent factor and performed a GWAS on the factor. Atrial fibrillation deteriorated the fit of the latent factor and it was therefore excluded. This was in line with results that showed that atrial fibrillation was substantially less genetically correlated with the ASCVDs than they were with each other. Combined, these results suggest that atrial fibrillation and ASCVDs have partly distinct sources of genetic variation. We identified many loci for MDD-ASCVD, some of which were uniquely associated with the shared liability and not with the constituent traits. We found that heritability for the MDD-ASCVD latent factor was enriched for genes specifically expressed in vascular braincells, deep layer corticothalamic 6b (projecting to the thalamus), and midbrain-derived inhibitory neurons (predominantly located in the thalamus). This cell-type enrichment signature was not found for MDD or ASCVD alone, suggesting that a distinct mechanism involving thalamic circuits underlies the shared liability to MDD-ASCVD. Altered thalamic function 486 has indeed been implicated previously in CVD³⁶⁻³⁸ and MDD^{39,40}, and white matter integrity in thalamic radiations show associations with aortic area and myocardial wall thickness, suggesting that it has a role 488 in the 'heart-brain' connection⁴¹.

 MDD showed a high degree of genetic overlap with risk factors. We showed that MDD was substantially more polygenic than blood pressure traits, lipid traits, and C-reactive protein. In contrast, psychosocial/lifestyle traits were equally polygenic to MDD and showed a large degree of overlap with MDD. Interestingly, the local and variant-level analysis indicated that blood pressure traits shared a 494 substantial proportion of their risk variants with MDD (in line with a previous report⁴²), which was masked at the genome-wide level due to their opposing effect directions. Similarly, BMI and lipid traits showed discordant effect directions to MDD in overlapping risk variants as well as opposite directions in local genetic correlations. Finally, C-reactive protein shared almost three quarters of its risk variants with MDD, most of which were in the positive direction, indicating a genetic relationship between C-reactive protein and MDD that was masked by the large polygenicity of MDD. Overall, these findings

It is made available under a CC-BY 4.0 International license.

 refine our understanding of the polygenic overlap between MDD and risk factors shared between MDD and CVD, and indicate that it is stronger and more complex than has previously been reported.

We estimated genome-wide genetic correlations between MDD and CVD adjusting for risk factors and

found that psychosocial/lifestyle factors explain a substantial part of the genetic correlation between

MDD and CVD and highlight loneliness as an important factor in the relationship between MDD and

 CVD.

 We found that, compared to MDD, the latent MDD-ASCVD factor was characterized by genetic correlations with immunometabolic factors and blood pressure, suggesting that the shared genetic liability to MDD and ASCVD is associated with an immunometabolic subtype of depression. The existence of an immunometabolic subtype of depression has been proposed previously, based on a long line of evidence of oxidative stress and neuroendocrine and inflammatory dysregulation in MDD, that 513 are preferentially associated with atypical symptoms of MDD (e.g., weight gain and oversleeping)⁴³. Indeed, we find that poor appetite or overeating is the MDD symptom with the consistently greatest genetic correlations to the CVDs, and it is among the most genetically correlated with MDD-ASCVD, while it is among the least correlated symptoms to MDD, although confidence intervals were too wide to be conclusive. We did not find large genetic correlations between sleep duration measured using an accelerometer over one week and the MDD-ASCVD factor. However, statistically significant variants for the MDD-ASCVD factor were strongly enriched in statistically significant variants for self-reported 520 short sleep duration $(<6$ hours per night)⁴⁴ suggesting that short sleep duration is more related to MDD-ASCVD comorbidity than overall sleep duration.

 Mental disorders that are highly comorbid with MDD, such as psychotic disorders, anxiety disorders 524 and PTSD, have also been shown to be associated with CVD⁴⁵. We find that ADHD, anxiety disorders and PTSD show genetic correlations with ASCVD and MDD-ASCVD. For ADHD and PTSD, the genetic correlation was similar between MDD and MDD-ASCVD. Future work should estimate latent factors representing shared and distinct sources of genetic covariance between MDD, ADHD, anxiety disorders, and PTSD and investigate how those factors relate to ASCVD.

 We found robust support for the likelihood of causal effects of MDD on CVD. Previous two-sample MR studies have observed associations between genetic liability to MDD and risk of coronary artery 532 disease but results for risk of heart failure have been inconsistent^{32,33,46,47}. Another study found an effect 533 of genetic liability to MDD on risk of stroke⁴⁸. Using more recent GWAS data, we confirmed an effect of genetic liability to MDD on coronary artery disease and stroke and found robust associations for heart failure and peripheral artery disease.

 Except for stroke, we found limited evidence for a causal effect of CVDs on MDD, which is contrary 538 to literature suggesting that such effects exist²⁴. The MDD sample is mainly based on large volunteer- based studies that might select against individuals with CVD. Indeed, participants in the UKB study are 540 healthier than the general population⁴⁹. In addition, interpretation of the MR estimate in this case is 541 complicated by the fact that CVD is a time-varying exposure with late age-of-onset⁵⁰. However, we do find that genetic instruments capture the well-established association between stroke and subsequent 543 MDD⁵¹. Therefore, the findings in our study offer some indication that the association between CVDs and subsequent MDD might have been overestimated in previous studies, possibly due to reverse causation, surveillance bias, or unmeasured confounding.

It is made available under a CC-BY 4.0 International license.

 We observed effects of genetic liability to MDD on most of the risk factors. We did not observe associations between genetic liability to MDD and blood pressure traits, although the presence of correlated and anti-correlated genetic components complicates interpretation. Indeed, using genetic instruments for the latent MDD-ASCVD factor, we did observe strong associations for pulse pressure. Previous MR studies of the association of C-reactive protein and IL-6 levels with MDD risk have also shown inconsistent results^{52,53}. We did not find an effect of genetic instruments for inflammatory markers on MDD. However, we did find associations between genetic liability to MDD and increased C-reactive protein levels, lipid levels, and type II diabetes, offering evidence that MDD might lead to long-term dysregulated immunometabolic pathways⁴³. Likewise, in line with previous evidence⁵⁴, we provided support for a causal effect of liability to MDD on smoking, which, in turn, can lead to inflammation. These results are in line with results based on genetic covariance estimated from all genetic variants that tentatively supported a mediating role for C-reactive protein and IL6 levels in the association between MDD and ASCVD.

 Analyzing risk factors explaining the effect of genetic liability to MDD on CVDs, we observed that only the association between genetic liability to MDD and coronary artery disease remained statistically significant after adjusting for psychosocial/lifestyle or metabolic covariates in a multivariable MR analysis. In addition, we found that smoking status attenuates the association between genetic liability 565 to MDD and peripheral artery disease, for which smoking is a particularly strong risk factor⁵⁵. Interestingly, we find that loneliness is an equally important factor explaining the relationship between MDD and peripheral artery disease, as well as heart failure, which is in line with the results from the adjusted genome-wide genetic correlation analysis discussed above. This emphasizes the need for interventions and preventive policies for reducing loneliness in the population, which has a further 570 increased prevalence during the COVID-19 pandemic and has been described as a pandemic itself^{56,57}.

 For most CVDs, no risk factor group could fully explain the genetic association between MDD and the CVD. This suggests that there are other mechanisms at work as well, which are not captured by the genetic data used in the study. For instance, GWAS measure lifetime genetic risk (up to the point of the maximum age in the sample) and cannot capture dynamic processes of cumulative and interactive risk. Relatedly, the statistical genetic tools we employed cannot formally distinguish between mediation and covariation pathways. Future studies should triangulate our findings using longitudinal observational and experimental data. Follow-up studies could also investigate the out-of-sample predictive power and clinical usefulness of polygenic risk scores for the shared liability to MDD-ASCVD, and evaluate their ability to identify individuals at risk for immunometabolic depression, as we could not investigate this due to sample overlap in the present study. Another limitation is that the bivariate MiXeR model was not able accurately estimate the polygenic overlap between MDD and IL6. The likely reason the MiXeR model failed in this case is because the two traits have very different genetic architectures with MDD being highly polygenic and IL6 being the least polygenic of the traits in the study, combined with the low sample size of the IL6 GWAS. In addition, to assess generalizability, these findings should be replicated with data from different ancestry sources. The lack of large genetic datasets from non- European populations is a crucial limitation that is widely acknowledged and yet difficult to circumvent. Observational studies have shown that MDD and CVDs could demonstrate different associations 589 depending on ancestry^{58,59}, and more genetic and non-genetic research is needed to understand such differences.

 To our knowledge, this is the first study moving beyond bivariate genetic overlap to investigate the latent genetic liability shared between MDD and ASCVD. Our triangulation of genome-wide, local, and variant-level methods provides compelling evidence that MDD and CVD, and their shared risk

It is made available under a CC-BY 4.0 International license.

 factors are more strongly overlapping genetically than has previously been reported. Similarly, using genome-wide, variant-level, and genetic instrument methods we show how shared risk factors explain the likely causal association between MDD and CVD. For both MDD and CVDs, we have used updated GWAS summary statistics, with an up to 3-fold increase in sample size compared to previous reports 599 $32-35$.

 This study dissected the architecture of polygenic overlap between MDD and CVD, and their shared risk factors to elucidate mechanisms linking these comorbid diseases. Our findings suggest that the shared genetic liability to MDD and ASCVD has a distinct genomic signature compared to MDD or any CVD separately. Moreover, the shared genetic liability shows stronger genetic correlations with 605 immunometabolic risk factors than MDD alone, in line with the idea of an inflammatory 60 or immunometabolic⁴³ subtype of MDD especially associated with atherosclerotic CVDs, highlighting the role of inflammation in MDD-ASCVD comorbidity. Indeed, we found that the HLA region is a hotspot of local genetic correlation between MDD and the CVD traits, that genetic liability to MDD is associated with C-reactive protein levels, and tentative support that inflammatory markers mediate some of the link between MDD and ASCVD. We highlight loneliness and smoking as important targets for intervention to reduce the risk of MDD and CVD, as well as CVD in individuals with MDD. Building on this work, tools can be developed to identify individuals at risk for developing immunometabolic depression (e.g., using blood tests of high-density lipoprotein and C-reactive protein

levels) and target them for cholesterol-lowering or anti-inflammatory medical interventions.

It is made available under a CC-BY 4.0 International license.

Methods

Data sources

 All data sources were summary statistics from the largest and most recent GWAS to date (see Supplementary Table 1). The MDD symptoms GWAS have not been published, although they have 620 been used in other publications⁶¹. The symptom GWASs were based on Patient Health Questionnaire (PHQ-9) items measured in the UKB, that captures most, but not all, core symptoms of MDD, and were 622 published online⁶². The disease trait GWASs were mostly based on electronic health record diagnoses. The physical activity and sleep duration traits were measured in the UKB using an accelerometer over a one-week period⁶³.

 The summary statistics were cleaned using the cleansumstats pipeline (https://github.com/BioPsyk/cleansumstats). SNPs were aligned and harmonized against reference data. Analyses were conducted on the TSD cluster, maintained by the University of Oslo, using singularity containers. Containers are packaged applications with their environmental dependencies that are used 630 to standardize analyses across different sites, ensuring correct software versions and parameters⁶⁴. All GWAS studies were ethically approved and were conducted in compliance with ethical guidelines. Ethics approval for the UK-Biobank study was given by the North West Centre for Research Ethics Committee (11/NW/0382). The work described here was approved by UK-Biobank under application number 22224.

Genetic overlap

Genome-wide genetic correlation

 To assess shared liability between MDD, CVD, MDD symptoms, and risk factors, we estimated genetic overlap on a genome-wide, polygenic, and local level. First, for the genome-wide level, we estimated 639 genetic correlation between each of the traits using LD score regression (LDSC²⁹). We excluded the human leukocyte antigen (*HLA*) region from the main analysis because its complex LD structure can bias both heritability and genetic correlation results⁶⁵ . However, a sensitivity analysis including the *HLA* region showed very similar results to the main analysis (not shown). Note that LDSC performs well in

- the presence of sample overlap.
- *Local genetic correlation*

645 We used Local Analysis of (co)Variant Association (LAVA 26) to assess genetic correlation in regions of the genome. We assessed local genetic correlation in 2,495 genomic regions that cover the autosomes and have been defined to minimize LD between the regions, while simultaneously keeping the regions approximately equal in size. These regions are provided with the LAVA software package. We only considered local genetic correlation in loci where both traits showed marginally significant heritability (*P*<0.05). For these loci, we adjusted local genetic correlation *P*-values for multiple testing using the Benjamini-Hochberg method. This adjustment was done separately for all pairs of traits considered. To match the results from LDSC and MiXeR, we excluded the *HLA* region from the main analyses. For local genetic correlation between MDD and the CVD traits, we performed an additional analysis in the *HLA* region.

Polygenic overlap

656 To investigate polygenic overlap beyond genetic correlation, we used MiXeR v1.3²⁵ to assess the number of shared and distinct non-zero genetic variants between MDD and another trait required to

It is made available under a CC-BY 4.0 International license.

 explain at least 90% of heritability in the two traits, referred to as 'causal' variants. Because it assesses overlap regardless of the effect direction of each variant, it gives a more adequate picture of localized correlations that could cancel each other out when estimating the genome-wide genetic correlation. We 661 excluded the *HLA* region, following the software recommendations²⁵. A sensitivity analysis of genetic overlap between MDD and the CVD traits including the *HLA* region showed very similar results to the main analysis (not shown). To assess stability of point estimates and estimate their standard deviations, we fitted the MiXeR model 20 different times for 2 million randomly selected SNPs with minor allele 665 frequency of at least 5%. The number of 20 runs follows recommendations published previously⁶⁶. The averaged results were then plotted in Venn diagrams to visualize the polygenic overlap. The MiXeR model was evaluated for each trait using by 1) comparing the AIC of the univariate MiXeR model with the LDSC model, which does not include a parameter to directly estimate polygenicity (Supplementary Table 5); 2) comparing the AIC of the bivariate MiXeR model with the AIC of the model with the least possible amount of polygenic overlap required to explain observed genetic correlation; 3) comparing the AIC of the bivariate MiXeR model with the AIC of the model with maximum amount of polygenic overlap (in such a model, all risk variants of the least polygenic trait are also risk variants of the other trait), and finally 4); evaluating the stability of the point estimates over the 20 runs (Supplementary 674 Table 6). These metrics have been described in detail previously⁶⁶. Except for the univariate test, the MiXeR model failed these checks for IL6, which was therefore excluded from the results. The MiXeR model performed poorly for the IL6 likely because it is a trait with low polygenicity and was measured in a relatively small sample (Extended Data Fig. 2, Supplementary Table 1).

To complement the univariate polygenicity analysis in MiXeR, we estimated polygenicity in a Bayesian

680 model implemented in $SBayesS^{30}$. We used a 15,000 sample MCMC chain with a 5,000-sample burn-

 in. The SBayesS methods did not converge for peripheral artery disease, possibly due to lower number of cases in the GWAS.

Shared liability to MDD and ASCVD

 To move beyond bivariate association to multivariate overlap, we conducted factor analysis on MDD 685 and the CVDs using Genomic SEM^{27} to assess if genetic latent factors could explain the genetic covariance between the traits. Genomic SEM uses LDSC to estimate the genetic covariance matrix and uses that in a SEM framework to identify multivariate relationships in the data. A Comparative Fit Index 688 CFI>.90, Standardized Root Mean Square Residual SRMR<.03, and standardized factor loadings β >0.3 were set as criteria for acceptable model fit. The best model fit was found for a factor with coronary artery disease, peripheral artery disease, heart failure, and stroke as indicators, which we interpret as a genetic factor for ASCVD. To model a genetic factor for shared liability to MDD and ASCVD, we defined a higher-order factor with this ASCVD factor plus MDD as indicators. The standardized loading of the first indicator (coronary artery disease) was set to 1. The residual variance of the ASCVD factor was forced to be 0, so that all variance was forced into the MDD-ASCVD factor. For comparison, we also estimated a common factor model for ASCVD without MDD, which is visualized in Extended Data Fig. 3a.

 Subsequently, we conducted a summary statistics-based GWAS on the MDD-ASCVD second-order latent factor to identify variants associated with this latent liability. We used the package-default diagonally weighted least squares estimator (DWLS). To derive genome-wide significant independent 701 loci we used the plink clumping procedure as implemented in $FUMA⁶⁷$, with R=0.6 and distance=250 kb, and reference data from 1000 genomes. To assess the heterogeneity of the SNP effects, we also fit

- an independent pathway model for each SNP, where each indicator was regressed on the SNP directly
- 704 instead of forcing the effect through the latent factor. We compare the common pathway $\chi^{2,\text{com}}_{SNP}$ to the

It is made available under a CC-BY 4.0 International license.

705 independent pathway $\chi_{SNP}^{2,ind}$ to derive Q_{SNP}. For our follow-up analyses, we filtered out all SNPs that 706 had effects that were more consistent with an independent pathway model at $P_{\text{Q}_{SNP}}$ <0.05. This stringent procedure filters out SNPs with heterogenous effects on MDD and the ASCVD factor. This way, variants are excluded that should be considered risk variants for MDD or CVDs separately rather than risk variants for MDD-ASCVD.

 Using FUMA, we checked if genome-wide significant SNPs for the MDD-ASCVD factor were enriched in genome-wide significant SNPs for traits in the GWAS-catalog. Then, to define unique loci, 713 we overlaid the independent genomic risk loci (now clumped at $R^2 = 0.1$ and 3000 kb window) for MDD- ASCVD with the risk loci for the constituent traits (MDD, peripheral artery disease, coronary artery disease, heart failure, and stroke). We used the 'intersect' function in bedtools to see if the risk regions were overlapping. If they were independent (according to the clump criteria) they were regarded as novel loci. We also identified genes whose regulation is significantly impacted by the top significant SNPs to interpret the biological implications of our findings. For this, we use eQTL estimates from 719 FUMA based on PsychENCODE reference data⁶⁸. Using the same procedures (though without filtering out heterogeneous SNPs) we conducted a GWAS for the the ASCVD genetic factor.

 To externally validate the latent MDD-ASCVD GWAS results, we computed PRS using LDpred2 (automatic mode with HapMap3 reference data). We compared the MDD-ASCVD PRS with a PRS based on MDD only, and with a PRS based on latent CVD without MDD. As a target sample we used the UKB. Summary statistics for ASCVD traits excluding the UKB were unavailable, and we chose to leave the UKB in for all traits. Sample overlap is likely to lead to overfitting, resulting in an inflation of explained variance. However, this is less of a concern when comparing PRS among themselves, rather than assessing absolute predictive value. As target phenotypes, we extracted CVD and MDD cases according to healthcare registry ICD codes from data field 41270 (see Supplementary Table 12). We used logistic regression analysis to predict case status from each PRS while controlling for the first 10 principal components for ancestry, sex, and year of birth. Continuous variables were standardized 732 and centered. We estimated Nagelkerke's R^2 to capture explained variance in the disease traits.

Tissue and cell-type analysis

 To gain insight into the biological mechanisms underlying the common liability to MDD and ASCVD, we performed a tissue and cell-type analysis using partitioned LDSC. Cell-type identification was based on the top decile of specifically expressed genes (referred to as top decile expression proportion [TDEP] 737 genes). The methodology has been described extensively in previous studies^{69–71}.

 We identified TDEP genes for brain cell-types from single-nucleus RNA-seq data measured in 740 dissections of three adult human post-mortem brain samples for the Adult Human Brain Atlas²⁸, part of the Human Cell Atlas. We used the manually annotated 31 superclusters and 461 clusters provided by 742 the atlas²⁸. We considered a curated set of 18,090 protein-coding autosomal genes, excluding those in the *HLA* region (because the method relies on LDSC), with expression in at least one of the 461 cell-clusters.

746 To establish TDEP genes for 16 human tissues, we utilized bulk RNA-seq data from GTEx $v8^{72}$. In line with previous research, we removed tissues with <100 donors and non-natural tissues (e.g., cell 748 lines) as well as testis tissues (expression outlier)^{69.} Prior to analysis in partitioned LDSC, we expanded

- the boundaries of TDEP genes by 100kb to include possible enhancers or promoters.
-

It is made available under a CC-BY 4.0 International license.

We tested the associations between GWAS traits and tissue/cell-types by investigating heritability

enrichment within the TDEP genes for each tissue/cell-type. To ensure that annotation enrichment could

not be better explained by other overlapping annotations, we adjusted for enrichment in 53 previously

defined baseline LDSC annotations (LDSC v1.0.1) of coding, UTR, promoter, intronic, various

755 enhancers, histone marks and other epigenetic marks, genomic regions⁷¹.

Pathways of association between MDD and CVD

Mediation in Genomic SEM

 We employed several different techniques to assess whether the association between MDD and CVD could be explained by shared risk factors. First, we estimated the genome-wide genetic correlations adjusting for the effects of risk factors using Genomic SEM. To aid interpretation, we added the covariates in groups, controlling for all trait groups separately (psychosocial/lifestyle, childhood maltreatment, metabolic, or inflammation traits; see Supplementary Table 1). We only included traits in the covariate groups that showed significant genome-wide genetic correlation with MDD. Note that we did not adjust for blood pressure traits, since none of the blood pressure traits showed genome-wide significant correlation with MDD. Attenuation of genetic correlation after adjustment was taken to indicate that shared risk factors account for some (or all) of the association between MDD and CVD.

 Next, we modeled the risk factors explicitly as mediators in Genomic SEM. If the direct effect is attenuated in the mediation model as compared to the covariate model, we view this as tentative support 770 for the existence of mediation (following procedures suggested by the software developers⁷³). Note however that this interpretation relies on untestable assumptions. Finally, we also tested the effects of individual risk factors (both as covariates and mediators) instead of grouping them.

Univariable and multivariable Mendelian randomization

 To test if the associations between MDD and CVD and risk factors were causal, we used Mendelian Randomization (MR). We assessed the effects of MDD on the CVDs and risk factors, the effect of the CVDs and risk factors on MDD, and the effect of latent MDD-ASCVD on risk factors. MR uses genetic variants as instrumental variables to assess the presence of causal effects of an 'exposure' on an 'outcome'. Core assumptions include that the instrumental variables are robustly associated with exposure and are not associated with the outcome (other than through the effect from exposure) or unmeasured confounders. We used the inverse variance weighted (IVW) estimate in the two-sample 781 MR R-package⁷⁴ as our main estimate. As instrument SNPs, we selected independent GWAS hits at $P \le 5 \times 10^{-8}$, $R^2 \le 0.001$, and distance $\le 5Mb$. In the analysis of the effect of genetic instruments of peripheral artery disease, physical activity, childhood maltreatment, and IL6 on MDD risk, we allowed instruments with higher *P*-values to be able to reach a total of 10 instruments (*P<*1e-5). For the MDD- ASCVD exposure, we used SNPs that showed no significantly heterogenous effects in the Genomic 786 SEM model $(Q_{pval} > 0.05$, see above), in order to limit the possibility of pleiotropic effects of this, by nature, heterogenous instrument.

 We performed several sensitivity analyses to test and adjust for violation of MR assumptions. All analyses were Steiger filtered, meaning that all SNPs that explained significantly more variance in the 791 outcome than the exposure were excluded as instruments⁷⁵. Weighted median and mode regression were 792 used to correct for effect size outliers that could represent pleiotropic effects⁷⁶. MR-Egger regression 793 was used to assess pleiotropy (pleiotropy leads to a significant intercept) and correct for it (unless I² indicated NOME violation of the NO Measurement Error [NOME] assumption, in which case we did 795 not report MR-Egger results 77,78). Second, to assess the strength of our instruments, we used Cochran's

796 . O to assess heterogeneity in the SNP effects⁷⁹ and the F-statistic to control for weak instrument bias⁸⁰.

It is made available under a CC-BY 4.0 International license.

 Third, we performed sensitivity analyses to gauge the effect of sample overlap in the GWASs that were used. Although sample overlap has been suggested to not greatly impact MR results when the source $GWASs$ have a large sample size and the overlap is limited⁸¹, we wanted to ensure sample overlap did not lead to bias in our findings. We assessed the genetic covariance intercepts for all MDD-trait pairs 801 from the LDSC analyses and observed that most were more than 1 SD away from 0, indicating that sample overlap was present (Supplementary Table 2). We repeated the analyses with MDD summary statistics leaving out the UKB sample, which is the sample responsible for most of the overlap and compared the results. Also, we repeated the analyses using Latent Heritable Confounder MR (LHC- MR³¹), which aims to correct for the presence of unmeasured heritable confounders as well as sample overlap.

 Subsequently, we test the adjusted pathways using multivariable MR (MVMR) analyses. The difference with the mediation test in Genomic SEM is that we now use instrumental variables that corroborate a causal interpretation. Because MVMR relies on simple regression analysis, it cannot formally test mediation; instead, the causal estimate is adjusted for the risk factor. To support a directional interpretation, we included only risk factors as mediators that were significantly affected by MDD according to the univariable analysis results. In MVMR, only an IVW estimate can be derived. Steiger filtering was performed on the exposure-outcome association. These analyses were not replicated in LHC, which does not accommodate multivariable analyses. For ease of interpretation, we again grouped 816 the mediators and adjusted for all mediators in a group concurrently. We only included a mediator in a group if it was significant in the univariate analysis. Additionally, we performed analyses adjusting for single mediators. We selected instruments for each variable in a model by a clumping step with the 819 same parameters as in the univariate MR case $(P<5\times10^{-8}, R²< 0.001)$. We then combined instruments for all variables in a model into a single set of instruments and performed another clumping step with the same parameters. These instruments were then aligned to the same effect allele. We estimated the 822 effect of genetic liability to MDD on CVD traits adjusting for covariates using multivariate MR with 823 the MVMR R-package⁸².

Data availability

 Links to download publicly available published GWAS summary statistics data used as inputs in this study are listed in Supplementary Table 1. Single nucleus RNA sequencing data in the adult human brain can be found at [https://github.com/linnarsson-lab/adult-human-brain.](https://github.com/linnarsson-lab/adult-human-brain) Researchers can request 828 access to the UK-Biobank data resources at [https://www.ukbiobank.ac.uk/enable-your-research/apply-](https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access) [for-access;](https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access) data for PRS analysis described in this study were accessed under accession number 22224. Gene expression data from human tissues can be found at [https://www.gtexportal.org/home/datasets.](https://www.gtexportal.org/home/datasets) 831 Summary statistics for MDDCVD are available upon request.

Code availability

 Code used for processing and analyzing data in this work will be uploaded to [https://github.com/jacobbergstedt.](https://github.com/jacobbergstedt) Code for singularity containers can be found at [https://github.com/comorment.](https://github.com/comorment)

It is made available under a CC-BY 4.0 International license.

References

- 1. Han, X. *et al.* Disease trajectories and mortality among individuals diagnosed with depression: a community-based cohort study in UK Biobank. *Mol Psychiatry* **26**, 6736–6746 (2021).
- 2. Nemeroff, C. B. & Goldschmidt-Clermont, P. J. Heartache and heartbreak—the link between depression and cardiovascular disease. *Nat Rev Cardiol* **9**, 526–539 (2012).
- 3. Kendler, K. S., Gardner, C. O., Fiske, A. & Gatz, M. Major Depression and Coronary Artery Disease in the Swedish Twin Registry. *Arch Gen Psychiatry* **66**, 857 (2009).
- 4. Xian, H. *et al.* Genetic vulnerability and phenotypic expression of depression and risk for ischemic heart disease in the Vietnam era twin study of aging. *Psychosom Med* **72**, 370–5 (2010).
- 5. Zhang, F., Cao, H. & Baranova, A. Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases. *Front Cardiovasc Med* **8**, (2021).
- 6. Als, T. D. *et al.* Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses. *Nat Med* **29**, 1832–1844 (2023).
- 7. Raynor, D. A., Pogue-Geile, M. F., Kamarck, T. W., McCaffery, J. M. & Manuck, S. B. Covariation of Psychosocial Characteristics Associated With Cardiovascular Disease: Genetic and Environmental Influences. *Psychosom Med* **64**, 191–203 (2002).
- 8. Vaccarino, V. *et al.* Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. *Eur Heart J* **41**, 1687–1696 (2020).
- 9. Penninx, B. W. J. H. Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms. *Neurosci Biobehav Rev* **74**, 277–286 (2017).
- 10. Roth, G. A. *et al.* Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol* **76**, 2982–3021 (2020).
- 11. Fan, M. *et al.* Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. *Eur Heart J* **41**, 1182–1189 (2020).
- 12. Valtorta, N. K., Kanaan, M., Gilbody, S., Ronzi, S. & Hanratty, B. Loneliness and social isolation as risk factors for coronary heart disease and stroke: systematic review and meta-analysis of longitudinal observational studies. *Heart* **102**, 1009–16 (2016).
- 13. Suglia, S. F. *et al.* Childhood and Adolescent Adversity and Cardiometabolic Outcomes: A Scientific Statement From the American Heart Association. *Circulation* **137**, (2018).
- 14. Schultz, W. M. *et al.* Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. *Circulation* **137**, 2166–2178 (2018).
- 15. Libby, P. *et al.* Atherosclerosis. *Nat Rev Dis Primers* **5**, 56 (2019).
- 16. Libby, P. *et al.* Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. *J Am Coll Cardiol* **72**, 2071–2081 (2018).
- 17. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).
- 18. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).
- 19. Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B. & Khandaker, G. M. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol Med* **49**, 1958–1970 (2019).
- 20. Suneson, K., Lindahl, J., Chamli Hårsmar, S., Söderberg, G. & Lindqvist, D. Inflammatory Depression-Mechanisms and Non-Pharmacological Interventions. *Int J Mol Sci* **22**, (2021).
- 21. Carney, R. M. & Freedland, K. E. Depression and coronary heart disease. *Nat Rev Cardiol* **14**, 145–155 (2017).

- It is made available under a CC-BY 4.0 International license.
- 22. Lu, Y., Wang, Z., Georgakis, M. K., Lin, H. & Zheng, L. Genetic Liability to Depression and Risk of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes. *J Am Heart Assoc* **10**, (2021).
- 23. Li, G. H.-Y. *et al.* Evaluation of bi-directional causal association between depression and cardiovascular diseases: a Mendelian randomization study. *Psychol Med* **52**, 1765–1776 (2022).
- 24. Hare, D. L., Toukhsati, S. R., Johansson, P. & Jaarsma, T. Depression and cardiovascular disease: a clinical review. *Eur Heart J* **35**, 1365–1372 (2014).
- 25. Frei, O. *et al.* Bivariate causal mixture model quantifies polygenic overlap between complex traits beyond genetic correlation. *Nat Commun* **10**, 2417 (2019).
- 26. Werme, J., van der Sluis, S., Posthuma, D. & de Leeuw, C. A. An integrated framework for local genetic correlation analysis. *Nat Genet* **54**, 274–282 (2022).
- 27. Grotzinger, A. D. *et al.* Genomic SEM Provides Insights into the Multivariate Genetic Architecture of Complex Traits. *Nat Hum Behav* 305029 (2018).
- 28. Siletti, K. *et al.* Transcriptomic diversity of cell types across the adult human brain. *Science (1979)* **382**, (2023).
- 29. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291 (2015).
- 30. Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex traits. *Nat Genet* **50**, 746–753 (2018).
- 31. Darrous, L., Mounier, N. & Kutalik, Z. Simultaneous estimation of bi-directional causal effects and heritable confounding from GWAS summary statistics. (2020) 902 doi:10.1101/2020.01.27.20018929.
- 32. Zhang, F., Cao, H. & Baranova, A. Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases. *Front Cardiovasc Med* **8**, (2021).
- 33. Li, G. H.-Y. *et al.* Evaluation of bi-directional causal association between depression and cardiovascular diseases: a Mendelian randomization study. *Psychol Med* **52**, 1765–1776 (2022).
- 34. Torgersen, K. *et al.* Shared genetic loci between depression and cardiometabolic traits. *PLoS Genet* **18**, e1010161 (2022).
- 909 35. Hagenaars, S. P. *et al.* Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* **183**, 309–330 (2020).
- 36. Wei, H.-L. *et al.* Disrupted resting-state functional connectivity of the thalamus in patients with coronary heart disease. *Heliyon* **9**, e13423 (2023).
- 37. Rosen, S. D. Silent Ischemia as a Central Problem: Regional Brain Activation Compared in Silent and Painful Myocardial Ischemia. *Ann Intern Med* **124**, 939 (1996).
- 38. Rosen, S. D. *et al.* Central nervous pathways mediating angina pectoris. *The Lancet* **344**, 147–150 (1994).
- 39. Greicius, M. D. *et al.* Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus. *Biol Psychiatry* **62**, 429–437 (2007).
- 40. Paul, E. R., Östman, L., Heilig, M., Mayberg, H. S. & Hamilton, J. P. Towards a multilevel model of major depression: genes, immuno-metabolic function, and cortico-striatal signaling. *Transl Psychiatry* **13**, 171 (2023).
- 41. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic resonance images. *Science* **380**, abn6598 (2023).
- 42. Torgersen, K. *et al.* Shared genetic loci between depression and cardiometabolic traits. *PLoS Genet* **18**, e1010161 (2022).

- It is made available under a CC-BY 4.0 International license.
- 43. Milaneschi, Y., Lamers, F., Berk, M. & Penninx, B. W. J. H. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. *Biol Psychiatry* **88**, 369–380 (2020).
- 44. Dashti, H. S. *et al.* Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates. *Nat Commun* **10**, 1100 (2019).
- 45. Shen, Q. *et al.* Psychiatric disorders and subsequent risk of cardiovascular disease: a longitudinal matched cohort study across three countries. *EClinicalMedicine* **61**, 102063 (2023).
- 46. Tang, B., Yuan, S., Xiong, Y., He, Q. & Larsson, S. C. Major depressive disorder and cardiometabolic diseases: a bidirectional Mendelian randomisation study. *Diabetologia* **63**, 1305– 1311 (2020).
- 47. Lu, Y., Wang, Z., Georgakis, M. K., Lin, H. & Zheng, L. Genetic Liability to Depression and Risk of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes. *J Am Heart Assoc* **10**, (2021).
- 48. Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun* **11**, 163 (2020).
- 49. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* **186**, 1026–1034 (2017).
- 50. Morris, T. T. *et al.* Interpretation of Mendelian randomization using a single measure of an exposure that varies over time. *Int J Epidemiol* **51**, 1899–1909 (2022).
- 51. Taylor, W. D., Aizenstein, H. J. & Alexopoulos, G. S. The vascular depression hypothesis: mechanisms linking vascular disease with depression. *Mol Psychiatry* **18**, 963–74 (2013).
- 52. Kappelmann, N. *et al.* Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. *JAMA Psychiatry* **78**, 161–170 (2021).
- 53. Khandaker, G. M. *et al.* Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol Psychiatry* **25**, 1477–1486 (2020).
- 54. Wootton, R. E. *et al.* Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. *Psychol Med* **50**, 2435–2443 (2020).
- 55. Behrooz, L., Abumoawad, A., Rizvi, S. H. M. & Hamburg, N. M. A modern day perspective on smoking in peripheral artery disease. *Front Cardiovasc Med* **10**, 1154708 (2023).
- 56. Office of the Surgeon General (OSG). *Our Epidemic of Loneliness and Isolation: The U.S. Surgeon General's Advisory on the Healing Effects of Social Connection and Community*. (2023).
- 57. Ernst, M. *et al.* Loneliness before and during the COVID-19 pandemic: A systematic review with meta-analysis. *American Psychologist* **77**, 660–677 (2022).
- 58. González, H. M. & Tarraf, W. Comorbid cardiovascular disease and major depression among ethnic and racial groups in the United States. *Int Psychogeriatr* **25**, 833–841 (2013).
- 59. Watkins, D. C., Assari, S. & Johnson-Lawrence, V. Race and Ethnic Group Differences in Comorbid Major Depressive Disorder, Generalized Anxiety Disorder, and Chronic Medical Conditions. *J Racial Ethn Health Disparities* **2**, 385–394 (2015).
- 60. Felger, J. C. & Miller, A. H. Identifying Immunophenotypes of Inflammation in Depression: Dismantling the Monolith. *Biol Psychiatry* **88**, 136–138 (2020).
- 61. Kappelmann, N. *et al.* Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms. *JAMA Psychiatry* **78**, 161 (2021).
- 62. Howrigan, D. P. *et al.* Nealelab/UK_Biobank_GWAS: v2. (2023) doi:10.5281/ZENODO.8011558.
- 63. Doherty, A. *et al.* GWAS identifies 14 loci for device-measured physical activity and sleep duration. *Nat Commun* **9**, 5257 (2018).
- 64. Akdeniz, B. C. *et al.* COGEDAP: A COmprehensive GEnomic Data Analysis Platform. *arXiv: 2212.14103* (2022).
- 65. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
- 66. Hindley, G. *et al.* Charting the Landscape of Genetic Overlap Between Mental Disorders and Related Traits Beyond Genetic Correlation. *Am J Psychiatry* **179**, 833–843 (2022).
- 67. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 68. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the human brain. *Science (1979)* **362**, (2018).
- 69. Bryois, J. *et al.* Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease. *Nat Genet* **52**, 482–493 (2020).
- 70. Skene, N. G. *et al.* Genetic identification of brain cell types underlying schizophrenia. *Nat Genet* **50**, 825–833 (2018).
- 71. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat Genet* **47**, 1228–1235 (2015).
- 72. Aguet, F. *et al.* The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science (1979)* **369**, 1318–1330 (2020).
- 73. Nivard, M. Mediation model in GenomicSEM. *https://gist.github.com/MichelNivard/04bf4ddcf3c32f905175de3058ca967a* (2018).
- 74. Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet* **27**, R195–R208 (2018).
- 75. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS Genet* **13**, e1007081 (2017).
- 76. Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* **46**, 1985–1998 (2017).
- 77. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* **44**, 512–525 (2015).
- 78. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int J Epidemiol* **45**, 1961–1974 (2016).
- 79. Bowden, J., Hemani, G. & Davey Smith, G. Invited Commentary: Detecting Individual and Global Horizontal Pleiotropy in Mendelian Randomization—A Job for the Humble Heterogeneity Statistic? *Am J Epidemiol* **187**, 2681–2685 (2018).
- 80. Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* **40**, 755–764 (2011).
- 81. Mounier, N. & Kutalik, Z. Bias correction for inverse variance weighting Mendelian randomization. *Genet Epidemiol* **47**, 314–331 (2023).
- 82. Sanderson, E., Spiller, W. & Bowden, J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. *Stat Med* **40**, 5434–5452 (2021).
-
-

It is made available under a CC-BY 4.0 International license.

Acknowledgments

 This work was supported by European Union's Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant #847776). JAP was supported by the the US National Institutes of Mental Health (R01MH123724). NP was supported by the Marie Skłodowska-Curie Actions Grant 801133 (Scientia fellowship) and RCN 300309. JLT is supported by a European Research Council (ERC) Starting grant (UNRAVEL-CAUSALITY, grant number 101076686) and by Foundation Volksbond Rotterdam. CML is part-funded the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. AMM is supported by the Wellcome Trust (220857/Z/20/Z) and UKRI (MR/W014386/1). ADB was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, "CoCA"), NIH/NIMH (1R01MH124851-01). OA was supported by the European Union's Horizon 2020 research and innovation program (grant agreement No 847776 and 964874), Research Council of Norway (223273, 296030, 326813). PFS gratefully acknowledges support from the Swedish Research Council (Vetenskapsrådet, award D0886501), the US National Institutes of Mental Health (R01s MH124871, MH121545, and MH123724), and the Horizon 2020 Programme of the European Union (grant agreement No 847776). LY was supported by the European Research Council (grant agreement ID 101042183). The authors acknowledge HERMES and CARDIoGRAMplusC4D consortia for contributing data and guidance. The PRS analyses have been conducted using the UK-Biobank Resource under Application Number 22224. They were enabled by resources in project sens2017519 provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) at UPPMAX, funded by the Swedish Research Council through grant agreement no. 2022- 06725. This work was performed on Services for Sensitive Data, University of Oslo, with resources provided by UNINETT Sigma2, the national infrastructure for high performance computing and data storage in Norway.

Author contributions

 This study was conceived by JB, PFS, YL, and FF. It was supervised by YL and FF. JB, JAP, and ZM were responsible for the main analyses, visualization, and the drafting of the manuscript. AH performed the tissue expression analyses with help and supervision from SY, JHL, and PFS, who also helped with the writing and interpretation of these results. NP was involved in providing and cleaning GWAS summary statistic data. DJAS supervised the Genomic SEM analysis and JLT the MR analyses. OF and AS were involved in providing the containerized software used in this project and supervising the MiXeR analyses. JJM, QS, SH, PT, AB, and TW contributed to interpreting findings. CML, AMM, TDA, and ADB were responsible for the MDD GWAS summary statistics and were involved in the interpretation of findings. SH helped with UKB data access and curation for the PRS analyses. SH, UVA, OA, PFS, YL and FF provided suggestions and expert supervision and contributed to the writing. All authors have read and provided feedback on the manuscript.

Competing interests

 CML sits on the SAB of Myriad Neuroscience and has received speaker/consultancy fees from SYNLAB and UCB. OAA is a consultant to Cortechs.ai, and has received speaker's honoraria from Lundbeck, Janssen and Sunovion. PFS has receieved consulting fees from and is a shareholder of Neumora therapeutics. Other authors declare no competing interests.

1061 1062

Extended Data Fig. 1 | Genetic correlation of MDD and MDD symptoms with CVDs.

(a) Results are based on LD Score Regression analysis. Points and error bars represent genetic correlation and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. **(b)** Local genetic correlation between MDD and CVDs in 16 loci in the HLA region. Only loci with marginally significant local heritability for both traits are shown. Points above the vertical line are significant based on multiple testing adjustment for considered loci performed for each CVD trait separately.

MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease

It is made available under a CC-BY 4.0 International license.

1064 **Extended Data Fig. 2 | Genetic correlation and polygenicity for MDD, CVD, and risk factors.**

- 1065 1066 1067 1068 1069 **(a)** Heatmap of the genetic correlations between MDD, the CVDs, and the risk factors, with the color indicating the effect direction (negative: red, positive: blue) and the size and shade of the square illustrating the size of the correlation. Results are based on LD Score Regression analysis. **(b)** Estimates of number of non-zero variants for from SBayesS for each trait (y-axis) and estimates of non-zero variants required to explain 90% of trait heritability for each trait from MiXeR (x-axis) for MDD, the CVDs, and the risk factors. Note that for PAD polygenicity
- 1070 estimates did not converge for SBayeS, possibly because of few number of cases.
- 1071 MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery
- 1072 Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical
- 1073 activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-
- 1074 High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein
- 1075
- 1076
- 1077

It is made available under a CC-BY 4.0 International license.

1078 **Extended Data Fig. 3 | Common latent factor underlying atherosclerotic CVD.**

(a) Latent atherosclerotic CVD (ASCVD) model, defined by stroke, peripheral artery disease (PAD), heart failure (HF), and coronary artery disease (CAD). All 'observed' traits are based on GWAS summary statistics. Results are from confirmatory factor analysis in Genomic SEM, and standardized factor loadings are given for each path. Circular dashed arrows give the trait variance. (**b)** Manhattan plot of the GWAS on ASCVD, with each dot representing a SNP with its position on the x-axis and its *P*-value on the y-axis. Genome-wide significant SNPs with a significant heterogeneity Q_{SNP} (with a strong effect on one or some of the indicators that was not well explained through the common latent factor) are displayed in grey. The dashed line indicates the genome-wide significance threshold $(P<5e-8)$.

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

1080 **Extended Data Fig. 4 | The genomic signature of MDD-ASCVD.**

- 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 **(a)** Enrichment for the MDD-ASCVD GWAS SNPs in genome-wide significant SNPs for traits in the GWAS catalog computed using FUMA. The traits are as reported in the original study. Note that sleep duration here is a dichotomization of self-reported sleep. Full name in GWAS catalog of the trait "Coronary artery disease*" is "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)". The dashed black line indicates the significance threshold after Benjamini-Hochberg adjustment. Adjustment for multiple testing was conducted over all traits in the GWAS catalog (>3500 traits). **(b)** The five SNPs that were significantly associated with MDD-ASCVD, but not with any of the constituent traits, with their *P*-value in the GWAS of the constituent traits. The dashed line indicates the genome-wide significance threshold (*P*<5e-8). **(c)** Genetic correlation of PHQ-9 MDD symptoms with MDD, and MDD-ASCVD, with bars representing 95% confidence intervals. Results are based on LD Score Regression analysis. **(d)** Genetic correlation of MDD, MDD-ASCVD, and ASCVD with five psychiatric disorders, with bars representing
- 1092 95% confidence intervals. Results are based on LD Score Regression analysis.
- 1093 ADHD = Attention Deficit and Hyperactivity Disorder; PTSD = Posttraumatic Stress Disorder.
- 1094
- 1095

It is made available under a CC-BY 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.01.23294931;](https://doi.org/10.1101/2023.09.01.23294931) this version posted January 29, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

Extended Data Fig. 5 | Genetic correlation between CVD and risk factors

Results are based on LD Score Regression analysis. Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. Open dots indicate a non-significant genetic correlation.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

1097

Extended Data Fig. 6 | Genetic correlation between MDD traits and risk factors

Results are based on LD Score Regression analysis. Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. Open dots indicate a non-significant genetic correlation.

MDD=Major Depressive Disorder; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

It is made available under a CC-BY 4.0 International license.

1098

Extended Data Fig 7 | Local genetic correlations between MDD and risk factors.

Volcano plots based on LAVA results. Local genetic correlation between MDD and each of the risk factors (x-axis) and the corresponding -log10 transformed *P-*value (y-axis). Correlations were estimated in the loci that showed marginally significant local heritability in 2,495 considered genomic regions. Loci exceeding the horizontal line are significant at P_{FDR} <.05. Multiple testing was adjusted for individually for each trait over considered loci. Psychosocial=Psychosocial/Lifestyle; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

1099

Extended Data Fig. 8 | Genetic correlation between MDD and CVD when adjusting for individual risk factors Results from Genomic SEM. Bars represent 95% confidence intervals. Reference estimates of the association without any adjustment are printed in black.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

1100

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

Extended Data Fig. 9 | Assessment of evidence for causal associations between MDD, CVD, and risk factors.

Results from univariable and multivariable Mendelian randomization (MR) analysis (Inverse variance weighted estimates are shown**) (a)** Effect of liability to MDD (exposure) on CVD and risk factors (outcomes) after excluding the UKB sample from MDD (which was responsible for most of the sample overlap in the exposure and outcome GWAS summary statistics). **(b)** Estimated fffect of CVD and risk factors on MDD after excluding the UKB. **(c)** Results from LHC-MR, that corrects for heritable confounders and sample overlap, with the standard inverse variance weighted MR estimate given as reference, for the effect of MDD on CVD and risk factors. **(d)** Effect of liability to MDD-ASCVD on outcomes and risk factors. **A-c** Statistically significant pleiotropic estimates are indicated with a red asterisk. The term beta refers to the log odds ratio.

Psychosocial=Psychosocial/Lifestyle; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

1104

Extended Data Fig. 10 | Effects of liability to MDD on CVDs when adjusting for individual risk factors

Results from multivariable Mendelian randomization. Bars represent 95% confidence intervals. Reference estimates of the association without any adjustment are printed in black.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein